The importance of STING for the onset of anti-tumor immune responses also becomes evident during therapeutic intervention, since utilizing synthetic CDN derivate-based vaccines, which are used by cGAS for the production of the STING ligand cGAMP, in different poorly immunogenic tumor models induced tumor regression in contrast to PD-1 monotherapy [223]. This evidence concerns the gene STING1 and neoplasm.